21 completed, 12 unknown, 6 terminated, 2 suspended. 45 Phase 3, 14 Phase 2.
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Secutrelvir, Placebo - SARS-CoV-2 | Phase 3 | Recruiting | Shionogi | 2000 | 2026-09-14 | 2026-10-26 |
| A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults Investigational mRNA-1273.815, Licensed Spikevax Vaccine - SARS-CoV-2 | Phase 3 | Completed | ModernaTX, Inc. | 217 | 2024-04-08 | 2025-05-25 |
| A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age mRNA-1083, Placebo, Influenza Vaccine - SARS-CoV-2, Influenza | Phase 3 | Completed | ModernaTX, Inc. | 8061 | 2023-10-19 | 2025-07-01 |
| A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 VYD222 (pemivibart), Normal saline - COVID-19, SARS-CoV-2 | Phase 3 | Completed | Invivyd, Inc. | 790 | 2023-09-08 | 2024-12-09 |
| Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad LVRNA009, CoronaVac® - SARS-CoV-2 | Phase 3 | Unknown | AIM Vaccine Co., Ltd. | 1100 | 2023-04-01 | 2023-02-02 |
| Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution - SARS-CoV-2 | Phase 3 | Unknown | AIM Vaccine Co., Ltd. | 9800 | 2023-03-25 | 2023-04-19 |
| A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 LVRNA009, 0.9%NaCl - SARS-CoV-2 | Phase 3 | Unknown | AIM Vaccine Co., Ltd. | 34000 | 2023-01-30 | 2023-02-21 |
| A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age mRNA-1273.214, mRNA-1273.815 - SARS-CoV-2 | Phase 3 | Completed | ModernaTX, Inc. | 1807 | 2022-06-21 | 2025-11-26 |
| Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3 Xagrotin, Green tea - Sars-cov-2 | Phase 3 | Unknown | Biomad AS | 3000 | 2022-06-01 | 2022-03-17 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 mRNA-1273.529, mRNA-1273, mRNA-1273.214 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 3548 | 2022-02-16 | 2024-08-09 |
| Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Angiotensin 1-7, Placebos - Coronavirus, Respiratory Failure | Phase 2 / Phase 3 | Unknown | Erasme University Hospital | 60 | 2021-12-30 | 2021-08-02 |
| A Study of S-268019 for the Prevention of COVID-19 S-268019-b, Placebo - SARS-CoV-2 | Phase 3 | Completed | Shionogi | 9902 | 2021-12-25 | 2025-11-28 |
| A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Withdrawn | CureVac | 2021-10-01 | 2021-08-20 | |
| A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above SARS-CoV-2 mRNA Vaccine, Placebo - COVID-19, SARS-CoV-2 | Phase 3 | Unknown | Walvax Biotechnology Co., Ltd. | 28000 | 2021-07-22 | 2021-11-18 |
| Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults AZD1222, AZD2816 - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | AstraZeneca | 2843 | 2021-06-27 | 2024-09-19 |
| EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19 Half dose of ChAdOx1 nCoV-19 (AZD1222), Standard dose of ChAdOx1 nCoV-19 (AZD1222) - SARS-CoV-2 | Phase 2 / Phase 3 | Unknown | Federal University of Espirito Santo | 29637 | 2021-06-01 | 2021-09-28 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants mRNA-1273.211, mRNA-1273, mRNA-1273.617.2 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 5161 | 2021-05-28 | 2025-02-28 |
| COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Terminated | CureVac | 129 | 2021-04-22 | 2022-05-13 |
| A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants mRNA-1273 - SARS-CoV-2 | Phase 3 | Completed | ModernaTX, Inc. | 234 | 2021-04-16 | 2024-06-18 |
| To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 SCTA01, Placebo - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Not yet recruiting | Sinocelltech Ltd. | 690 | 2021-03-28 | 2021-03-29 |
Showing 20 of 45. Sign in to see all of them.
COVID-19 (34) · Coronavirus Infections (16) · Severe Acute Respiratory Syndrome (6) · Virus Diseases (6) · Anosmia (1) · Influenza, Human (1) · Olfaction Disorders (1) · Respiratory Insufficiency (1)
Coronaviridae Infections (36) · Infections (36) · Nidovirales Infections (36) · RNA Virus Infections (36) · Respiratory Tract Diseases (36) · Respiratory Tract Infections (35) · Lung Diseases (34) · Pneumonia (34) · Pneumonia, Viral (34) · Virus Diseases (30) · Coronavirus Infections (20) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Orthomyxoviridae Infections (1) · Pathological Conditions, Signs and Symptoms (1)
2019-nCoV Vaccine mRNA-1273 (6) · CVnCoV COVID-19 vaccine (5) · Hydroxychloroquine (4) · mRNA-1273.214 COVID-19 vaccine (4) · Azithromycin (3) · ChAdOx1 nCoV-19 (3) · remdesivir (3) · Ascorbic Acid (2) · LVRNA009 COVID-19 vaccine (2) · Sodium Chloride (2) · Amantadine (1) · COVID-19 Vaccines (1) · Colchicine (1) · Control Groups (1) · Drug Combinations (1)
ModernaTX, Inc. (9) · CureVac (4) · AIM Vaccine Co., Ltd. (3) · AstraZeneca (2) · Capital Medical University (2) · Shionogi (2) · University of Washington (2) · Biomad AS (1) · Biomed Industries, Inc. (1) · Erasme University Hospital (1) · Federal University of Espirito Santo (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Hospital San Vicente Fundación (1) · Independent Public Clinical Hospital No. 4 in Lublin (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1)
United States (19) · Spain (4) · United Kingdom (4) · Colombia (3) · Dominican Republic (3) · Mexico (3) · Peru (3) · Argentina (2) · Belgium (2) · Brazil (2) · Chile (2) · China (2) · Germany (2) · Japan (2) · Pakistan (2)
Aamer Ikram (1) · Alejandro Llanos, MD, PhD (1) · Alexandra Lansky, MD (1) · Ann Falsey, MD (1) · Catherine Oldenburg, ScD, MPH (1) · Christine Johnston, MD, MPH (1) · Eduardo Gotuzzo, MD (1) · Emanuele Nicastri, MD (1) · Fan Zhang (1) · Filippo Annoni, MD (1) · Gray Heppner (1) · James Neaton, PhD (1) · Konrad Rejdak, Professor, PhD, MD (1) · Lloyd Tran, PhD (1) · Magda Sobieszczyk, MD (1)
PMID 34350582, PMID 34473343, PMID 36695483, PMID 37385888, PMID 38518789, PMID 39225478, PMID 32423584, PMID 32448345, PMID 32493478, PMID 32690074, PMID 33066761, PMID 33284679, PMID 33378609, PMID 33681731, PMID 33688640, PMID 33715160, PMID 33743799, PMID 33935163, PMID 34011199, PMID 34269813, PMID 34379915, PMID 34401888, PMID 34461322, PMID 34551225, PMID 34587382, PMID 34826381, PMID 34870630, PMID 35093205, PMID 35145311, PMID 35165421, PMID 35291289, PMID 35390511, PMID 35535503, PMID 35544369, PMID 35604806, PMID 35701541, PMID 35780813, PMID 35785530, PMID 36055877, PMID 36106642, PMID 36112399, PMID 36202997, PMID 36216961, PMID 36260859, PMID 36348276, PMID 36610390, PMID 36713413, PMID 36828654, PMID 36849996, PMID 37075127
2023 (1), 3UL1TR002243-04S3 (1)